Loading...
Higher Alzheimer disease (AD) blood-based biomarker levels may lead to faster cognitive decline, but specific cognitive domains have not been tied clearly to specific biomarkers. The researchers of this clinic-based prospective study evaluated whether AD blood-based biomarkers affected cognitive and functional trajectories in individuals aged ≥60 years with subjective cognitive complaints or mild cognitive impairment. At baseline, participants were free of dementia; blood biomarker measurements included β-amyloid (Aβ) 40 and 42, phosphorylated tau (p-tau181), and neurofilament light chain (NfL) levels. Cognitive assessments, conducted annually for 5 years, included performance on global cognition, verbal episodic memory, semantic fluency, c…